Concepedia

Zeynep Eroglu

ZE

Statistics

Publications

4

Citations

120

H-Index

4

Active since

2022

Affiliations

Moffitt Cancer Center(Current)

University of Pittsburgh Medical Center

University of California, Los Angeles

UPMC Hillman Cancer Center

National Cancer Institute

Zeynep Eroglu is an author at Moffitt Cancer Center specializing in cancer therapeutics, tumor immunity, and medicine.

Top concepts

Publications per year

2022–2022

4

Publications

4

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

Gerald S. Falchook, Antoni Ribas, Diwakar Davar et al. · Journal of Clinical Oncology · 2022 · 73 citations

, , +17

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Kari Kendra, James Moon, Zeynep Eroglu et al. · Journal of Clinical Oncology · 2022 · 21 citations

, , +21

Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

Kara M. Schenk, Julie E. Stein, Sunandana Chandra et al. · Journal of Clinical Oncology · 2022 · 16 citations

, , +23

AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.

Antoni Ribas, Zeynep Eroglu, Jose Manuel Manuel Trigo Perez et al. · Journal of Clinical Oncology · 2022 · 10 citations

1–4 of 4